// App-Quantinova.ai

: T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Jessica Leonard

Principal Investigators

  • Yoko Kosaka

  • Pavani Malla

  • Brandon Hayes-Lattin

  • Adam J. Lamble

  • Brian J. Druker

  • Jeffrey W. Tyner

  • Bill H. Chang

  • Evan F. Lind

Medical Centers

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR

  • Oregon Health and Science University, Portland, OR

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Pediatric Hematology-Oncology, Seattle Childrens Hospital, Seattle, WA

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Department of Cell & Developmental Biology, Oregon Health & Science University, Portland, OR

  • OHSU, Portland, OR

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 19

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 4

  • Cluster of differentiation 45

  • Cluster of Differentiation 56

  • Cluster of differentiation 8A

  • Cytokine

Drug/Treatment

  • Blinatumomab

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • Hypaque Injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved